Trial Profile

Efficacy and safety of everolimus-eluting stent (Xience Prime) in long coronary lesions

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 03 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary)
Indications Coronary artery disease; Coronary artery restenosis
Focus Therapeutic Use
Acronyms LONGPRIME

Most Recent Events

20 Oct 2015 New trial record
02 Sep 2015 Results presented at ESC Congress 2015: Annual Congress of the European Society of Cardiology.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com